STOCKHOLM, Oct. 27, 2023 /PRNewswire/ — Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line HCC July – September Financial summary for the quarter Net turnover amounted to SEK 0.8 (1.1) million….